Status:

COMPLETED

Efficacy of NOV-002 in Combination With Carboplatin in Chemotherapy-resistant Ovarian Cancer

Lead Sponsor:

Cellectar Biosciences, Inc.

Collaborating Sponsors:

Massachusetts General Hospital

Dana-Farber Cancer Institute

Conditions:

Ovarian Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

The purpose of this trial is to determine the tumor response rate of NOV-002 plus carboplatin in a cohort of women with platinum resistant cancer of ovarian origin.

Detailed Description

The purpose of this research study is to learn if adding NOV-002 to the chemotherapy drug carboplatin works in treating ovarian cancer. Platinum containing drugs such as carboplatin are the standard t...

Eligibility Criteria

Inclusion

  • Histologically confirmed epithelial ovarian, primary peritoneal, or fallopian tube cancer
  • ECOG 0-1
  • Platinum resistant or refractory disease defined as progressive disease within 6 months of completing or while receiving their last platinum containing regimen
  • Measurable disease

Exclusion

  • History of other malignancies within 2 years except for adequately treated carcinoma in situ of the cervix, ductal carcinoma in situ of the breast, incidental stage I endometrial cancer, basal or squamous cell skin cancer
  • Major surgery within 2 weeks of study entry
  • History of anaphylactic shock with prior platinum chemotherapy
  • Known history of central nervous system (CNS) metastases unless subject has had treatment with surgery or radiation therapy and is neurologically stable
  • Treatment with more than 3 lines of chemotherapy
  • Chronic use of systemic corticosteroids

Key Trial Info

Start Date :

July 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2008

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT00345540

Start Date

July 1 2006

End Date

June 1 2008

Last Update

March 10 2015

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Dana Farber Cancer/Partners Cancer Care

Boston, Massachusetts, United States, 02115

2

Massachusetts General Hospital

Boston, Massachusetts, United States, 02115